Logo (pure-white background + navy borde

Diverse Health Hub

  • Facebook
  • Twitter
  • Instagram

© 2020 Diverse Health Hub, LLC

Multiple Myeloma

Multiple myeloma is a blood disorder that begins in the plasma cells. Studies have shown that minority populations are at an elevated risk for myeloma, yet are unrepresented in research. Through a series of educational programs, Diverse Health Hub will spotlight important news impacting myeloma patients and their families.

Myeloma Programs

Screen Shot 2019-12-15 at 10_edited.jpg

Does Treatment Adherence in Myeloma Impact Outcomes?

Myeloma expert Dr. Sikander Ailawadhi of Mayo Clinic breaks down the importance of treatment adherence and disease management in multiple myeloma in order to get the maximum benefit. In Dr. Ailawadhi's own words: "In myeloma it has been shown again and again, if you use the right treatment for the right duration and you get a deep response, you are more likely to do better."

Screen Shot 2019-12-15 at 10_edited.jpg

ASH 2019: Good News for Myeloma Treatment Today, Still Addressing Race-Associated Risks

Respected myeloma expert, Dr. Ajay Kumar Nooka, provides an update from the 61st American Society of Hematology (ASH) meeting. Dr. Nooka shares why this is a good time in myeloma research and the important work that remains around myeloma treatment disparities for people of color.

Screen Shot 2019-12-15 at 10_edited.jpg

How Can Myeloma Patients Facing Disparities Be More Proactive in Their Care?

Dr. Victoria Vardell of the Huntsman Cancer Institute of Utah discusses her study where key findings reveal Black patients are less likely to receive a stem cell transplant (SCT) and encourages patients to ask questions of their providers until they have a complete understanding.

Screen Shot 2019-12-15 at 10_edited.jpg

2020 Shaping Up To Be Big Year for Multiple Myeloma Treatment

Dr. Sikander Ailawadhi of Mayo Clinic provides high-level highlights for multiple myeloma from the 61st American Society of Hematology (ASH) Meeting in Orlando, Florida.

Screen Shot 2019-12-15 at 10_edited.jpg

ASH 2019: Disparities Around Accessing Health Technology Revealed for a Subset of Myeloma Patients

Is the cost of care in treating multiple myeloma higher for certain populations? In this Diverse Health Hub interview, Dr. Sikander Ailawadhi of Mayo Clinic, discusses disparities around access to care in multiple myeloma from the 61st American Society of Hematology (ASH) Meeting in Orlando, Florida.